Gino Santini is a senior advisor providing financing and business consulting services to venture capital, pharmaceutical and biotech companies. He currently serves as a member of the board of directors of Allena Pharmaceuticals, Inc. (ALNA), Intercept Pharmaceuticals, Inc. (ICPT) and Horizon Pharma plc (HZNP), as well as several privately held companies.
Previously, Mr. Santini served on the board of directors of AMAG Pharmaceuticals Inc. (AMAG), Vitae Pharmaceuticals, Inc. (VTAE) and Sorin S.p.A., a company traded on the Italian Stock Exchange. He retired as Senior Vice President of Corporate Strategy and Business Development of Eli Lilly after a career with the company of over 27 years. He had held the position since 2007 and had served as a member of the company’s Executive Committee. Previously, he had served as President of US Operations at Eli Lilly. Prior to that position, Mr. Santini served as Pharmaceutical Director for the Lilly affiliate in Belgium, and as General Manager of Eli Lilly Compania de Mexico in Mexico City. Mr. Santini also served as Vice President of Corporate Strategy and Business Development at Eli Lilly, with the responsibility for the Public Policy and Development Group and was named President of the Women’s Health Business Unit. Prior to that, he held positions of increasing responsibility within the company. Mr. Santini received a degree in mechanical engineering from the University of Bologna, Italy, and a Master of Business Administration degree from the University of Rochester.